Safety and efficacy of scallop-derived plasmalogen on patients with chronic fatigue syndrome: an open-label study

Safety and efficacy of scallop-derived plasmalogen on patients with chronic fatigue syndrome: an open-label study - Safety and efficacy of scallop-derived plasmalogen on patients with chronic fatigue syndrome: an open-label study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035054

Enrollment

Registered

2018-11-28

Start date

2018-12-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic fatigue syndrome

Interventions

Administration of the test food (0.5mg scallop-derived plasmalogen) twice per day for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ?Written consent obtained for the participation in this study ?Subjects aged 20 to 70 ?Subjects diagnosed as chronic fatigue syndrome

Exclusion criteria

Exclusion criteria: ?Subjects having ever taken scallop-derived plasmalogen ?Subjects who are pregnant or lactating ?Subjects judged ineligible for this study by the investigator

Design outcomes

Primary

Measure	Time frame
CFS questionnaire (baseline, 4W, 8W, 12W)	—

Secondary

Measure	Time frame
Plasmalogen levels of blood plasma and erythrocyte membrane Body temperature on awakening State-Trait Anxiety Inventory(form X) OSA Sleep Inventory Athens Insomnia Scale(MA)	—

Countries

Japan

Contacts

Public ContactChikako Wakana

The Japanese Plasmalogen Society General Manager

info@pls.jp092-273-2411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026